Clay Siegall is the President, CEO, and the Chairman of Board of Directors of a well-known company, Seattle Genetics. As a founder of the company, he has guided the small startup to become one of the leaders in producing treatment for cancer therapies. The company is specifically famous for producing antibody drug conjugates. Using a broad range of innovative technologies, diverse research, and extensive testing, Seattle Genetics was able to get approval from FDA for its product, ADCETRIS. After the approval of the drug in 2011, Clay Siegall played an instrumental role in marketing and distribution of the product convincing global partners to use it in their clinical research.
Currently, ADCETRIS has become a global brand, which is actively used in scientific research and treatment of cancer in more than 60 countries. Such is the demand of ADC technology that Clay Siegall is able to convince major pharmaceutical companies including Genentech, AbbVie, GlaxoSmithKline and Pfizer, to use the ADC license for multiple medical purposes. To secure funding for ADC and other drugs, Clay Siegall has also secured more than $1.2 Billion through private and public financing. His recent research focuses on conducting a Phase 3, or advanced, clinical trial to diagnose Hodgkin lymphoma.
In fact, Clay Siegall is taking a keen interest in fight lymphomas and other forms of Cancer. According to him, the company is actively pursuing research in developing 12 other drugs that can prove important for treating several incurable diseases. Accordingly, another drug 33A is in the pipeline to acquire permission for Phase 3 clinical trials. As for Clay Siegall, establishing new benchmarks for cancer treatment are important, which are reflected in his career, which includes working with Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute. Perhaps, Clay Siegall is destined to continue his life-long mission of finding cure for Cancer.